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ABSTRACT
Glutamine, the conditionally essential amino acid and most abundant amino acid in
human sera, is a key nutrient required for sustaining cell proliferation. Glutamine is
essential for nucleotide, protein, and lipid synthesis, all of which are essential for cell
proliferation. The mammalian target of rapamycin complex 1 (mTORC1) is a highly
conserved protein complex that acts as a sensor of nutrients, relaying signals for the shift
from catabolic to anabolic metabolism. While glutamine plays an important role in
activating mTORC1, the mechanism is not completely clear. Here we describe a Ragindependent mechanism of mTORC1 activation by glutamine that is dependent on
phospholipase D (PLD). PLD catalyzes the hydrolysis of phosphatidylcholine to generate
phosphatidic acid (PA) – a metabolite required for the stability and activity of both
mTORC1 and mTORC2. Suppressing the production of PA by PLD blocked mTORC1
activation by glutamine. It has been reported that glutamine stimulates mTORC1 through
an amino acid transporter that exchanges glutamine for leucine. However, our data
suggests that glutamine can stimulate PLD and mTORC1 independently of leucine, in an
ADP-ribosylation factor 1 (Arf1), RalA, and Rheb-dependent manner. α-ketoglutarate, a
downstream metabolite of glutamine, was able to rescue mTORC1 activation following
glutamine deprivation and also required Arf1 and PLD, but not Rag GTPases.
Collectively, our data describe a novel mechanism by which glutamine stimulates
mTORC1 in a PLD-PA-dependent manner. This pathway runs parallel to the leucinedependent, Rag-GTPase pathway for mTORC1 activation and likely represents a
compensatory mechanism for glutamine to activate mTORC1 in the absence of leucine.
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CHAPTER 1: INTRODUCTION

Glutamine Addiction
Cancer cells have an increased dependency on nutrients to support their continuous cell
growth and proliferation, resulting in the reprogramming of cellular metabolism
(Hanahan and Weinberg, 2011). In the 1920’s, Otto Warburg first made the observation
that cancer cells produced more lactic acid than normal cells, the result of increased
glucose uptake and aerobic glycolysis (Vander Heiden et al., 2009). Although most
cancer cells exhibit this ‘Warburg Effect’, it is a seemingly wasteful use of glycolysis
whereby glucose is metabolized to lactate, rather than entering into the mitochondria to
produce ATP (Vander Heiden et al., 2009). However, the increased dependency on
glycolysis allows for the shunting out of glycolytic intermediates to be used in other
biosynthetic pathways (Vander Heiden et al., 2009). Nonetheless, this results in a
decrease in the citric acid cycle reactions, leaving the cells with a void of cellular energy.
Glutamine is the most abundant amino acid in human sera and is consumed by
cancer cells at a significantly higher rate than any other amino acid (Wise and Thompson,
2010). Glutamine, originally thought to be a non-essential amino acid (NEAA), is
sometimes referred to as a ‘conditionally essential amino acid’, in that under
circumstances of increased cell proliferation, the need for glutamine to generate cellular
components exceeds the amount of glutamine that can be synthesized (Lacey and
Wilmore, 1990). Upon entering the cell, glutamine can be converted into glutamate by
glutaminase (GLS) or by enzymes involved in nucleotide biosynthesis, removing
glutamine’s amide group as a nitrogen source for the production of nucleotides and
NEAAs (Hensley et al., 2013) (Fig. 1.1). The resulting glutamate can be converted into
the citric acid cycle intermediate, α-ketoglutarate (αKG), by transaminases such as
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glutamate-oxaloacetate transaminase (GOT), producing αKG and aspartate from
oxaloacetate, or by glutamate dehydrogenase (GDH), generating αKG and free ammonia
(Hensley et al., 2013) (Fig. 1.1). In this way glutamine is able to replenish the citric acid
cycle in dividing cells where citrate exits the mitochondria to be used for fatty acid and
cholesterol biosynthesis (Wise and Thompson, 2010).
Due to glutamine’s important role in providing carbon and/or nitrogen for protein,
lipid, and nucleotide biosynthesis, many cancer cells have an increased dependency for
survival on exogenous glutamine, which has been termed ‘glutamine addiction’ (Wise
and Thompson, 2010). Oncogenic levels of Myc and K-Ras cause cells to engage in
higher levels of glutaminolysis through increased expression of GLS (Wise et al., 2008)
and GOT (Son et al., 2013), respectively. These oncogenes also increase expression of
the glutamine transporter, solute carrier family (SLC)1A5 transporter resulting in
increased uptake and addiction to glutamine (Toda et al., 2017; Wise et al., 2008) (Fig.
1.1).
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Figure 1.1: Overview of glutamine metabolism. Glutamine serves several roles in the cell through its
metabolism to αKG. K-Ras and c-Myc oncogenes drive glutamine uptake and metabolism via upregulation
of SLC1A5, GLS, and GOT protein levels.

Glutamine Activates mTORC1
Glutamine’s large role in amino acid biosynthesis makes it a useful sensor involved in the
regulation of protein translation. The mammalian target of rapamycin (mTOR) is a
central regulator of protein translation, and in particular, is responsive to glutamine levels
(Durán et al., 2012; Jewell et al., 2015; Nicklin et al., 2009). mTOR is a highly conserved
serine/threonine kinase and part of mTOR complex 1 (mTORC1), which exerts many of
its effects through its downstream effector, ribosomal subunit S6 kinase (S6K), in
response to nutrients – mainly amino acids, cellular energy levels and glucose (Laplante
and Sabatini, 2012). It has been suggested that signals that activate mTOR are some of
the most commonly activated signaling pathways in human cancers (Foster, 2013).
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Cancer cells need a much higher flux of metabolites towards anabolic pathways to
accommodate their high level of proliferation. mTOR assists in the metabolic
transformation from catabolism to anabolism. Additionally, mTOR can suppress
apoptosis, one of the cells primary defenses against cancer (Toschi et al., 2010). Thus,
cancer cells rely on mTOR signaling pathways for survival.

Amino Acid Sensing by mTORC1
mTORC1 is regulated by small guanosine triphosphatases (GTPases) in response to
amino acids. In humans, there are four Rag GTPases, which are part of the Ras GTPase
superfamily- Rag A and B, which are functionally equivalent, and Rag C and D which
are also functionally alike. Rag A/B interacts with Rag C/D to form a heterodimer on the
lysosome, and is inactive in the absence of amino acids. The Rags are regulated by the
Ragulator complex, the vacuolar H+-Adenosine Triphosphatase (v-ATPase) and the Gator
complex. The v-ATPase detects accumulation of lysosomal amino acids, which leads to
the activation of the v-ATPase’s proton pump, acidifying the lysosome (Bar-Peled and
Sabatini, 2014). This in turn activates the Ragulator’s guanine nucleotide exchange factor
(GEF) activity and inhibits Gator1’s GTPase-activating protein (GAP) (Bar-Peled and
Sabatini, 2014). Thus, upon stimulation with amino acids, Rag A/ B exchanges its bound
GDP for GTP to become active and bind to mTORC1, recruiting it to the lysosome (BarPeled and Sabatini, 2014). Here on the lysosome, GTP-bound Rheb directly activates
mTORC1. The tuberous sclerosis complex (TSC), the GAP for Rheb, acts as a negative
regulator of mTORC1 and is activated by AMP-activating kinase (AMPK), a sensor for
cellular energy, inhibiting mTOR when ATP levels are low (Inoki et al., 2003).
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Furthermore, AMPK is inhibited by the presence of glucose and amino acids, particularly
glutamine, which may be a significant factor in nutrient sensing by mTORC1 (Gleason et
al., 2007).
Although mTORC1 is activated in response to amino acids, leucine produces the
most significant response from mTOR and glutamine is necessary for maximum
mTORC1 activation (Nicklin et al., 2009; Wise and Thompson, 2010). Glutamine import
occurs through the SLC1A5 transporter (Nicklin et al., 2009) (Fig. 1.1). Some of this
glutamine can be rapidly exported in exchange for the influx of essential amino acids
(EAA), notably leucine, via SLC7A5/SLC3A2 (Fig. 1.1). Nicklin, et al. showed that
glutamine uptake and subsequent efflux is necessary for mTORC1 activation (Nicklin et
al., 2009). This study identified the importance of glutamine for mTORC1 activation by
leucine, in that leucine is incapable of stimulating mTORC1 in the absence of glutamine
or when SLC1A5 or SLC7A5 is inhibited (Nicklin et al., 2009). Further, Durán, et al.
showed that glutamine and leucine synergize to activate mTORC1 via enhanced
glutaminolysis and the production of αKG upstream of the Rag GTPases, which are
necessary for mTORC1 activation by most amino acids (Durán et al., 2012) (Fig. 1.2).
In addition, Jewell et al. identified a Rag-independent mechanism for mTORC1
activation by glutamine (Jewell et al., 2015). Briefly, they showed that leucine stimulates
mTORC1 in a Rag-dependent mechanism, whereas glutamine activates mTORC1 in a
Rag-independent mechanism (Jewell et al., 2015) (Fig. 1.2). Glutamine activates and
promotes mTORC1 translocation to the lysosome independently of Rag A/B and the
Ragulator and requires the ADP ribosylation factor (Arf) 1 GTPase and the v-ATPase
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(Fig. 1.2). In contrast, leucine requires the Rag-GTPases (Jewell et al., 2015) (Fig. 1.2).
Thus, mTORC1 senses different amino acids by different mechanisms.
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Figure 1.2: mTORC1 Activation by Glutamine in Rag-Independent and –Dependent Mechanisms. In
the Rag-dependent mechanism (left), glutamine is metabolized to α-ketoglutarate, which facilitates the
exchange for a GTP on RagA/B to recruit mTORC1 to the lysosome, for its subsequent activation (Durán
et al., 2012). Additionally, glutamine facilitates the uptake of leucine, which allosterically activates GDH,
stimulating α-ketoglutarate production (Gleason et al., 2007). Likewise, leucine itself stimulates mTORC1
activation in a Rag-dependent manner (Nicklin et al., 2009). In the Rag-independent mechanism (right),
glutamine utilizes the Arf1 GTPase and the vacuolar-ATPase (v-ATPase), with no requirement for Rag
A/B (Jewell et al., 2015).
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Phosphatidic Acid Stabilizes mTOR Complexes
Evidence has shown that there is a requirement for phosphatidic acid (PA) for the
stability and activation of both mTOR complexes (Toschi et al., 2009). PA can be
generated through three different pathways – diacylglycerol kinase (DGK),
phospholipase D (PLD), and lysophosphatidic acid acyl transferase (LPAAT). PA
production by DGK represents an input from growth factors, as DGK is responsive to
these signals. We have speculated that the de novo production of PA by LPAAT is
utilized as a sensor of glucose levels, as glucose provides the glycerol backbone for PA
(Menon et al., 2017). Likewise, PA is the parent phospholipid from which all other
phospholipids are produced. Thus, PA is a central point of membrane biosynthesis and
acts as a vital lipid second messenger (Foster, 2013). Of note is PLD, which can be
activated in response to a range of external stimuli to generate PA and provide a
mechanism for generating the PA needed for mTOR activation (Foster, 2013).
mTOR exists in two complexes - mTORC1 and mTORC2 – both of which are
able to integrate external stimuli to control protein synthesis, ribosome biogenesis and
autophagy (Sabatini, 2006) (Fig. 1.3). Both mTOR complexes are dependent on the
presence of PA, and in the absence of PLD-generated PA, the mTORC1 and mTORC2
complexes dissociate (Toschi et al., 2009). Previous work from our lab has identified
PLD-dependent mTORC1 sensing of glucose and the EAA – leucine, lysine and arginine
(Xu et al., 2011). This work provided a broader nutrient sensing role for PLD (Xu et al.,
2011). The significance of this lies in the fact that suppression of the PA-mTOR signaling
pathway in cancer cells may be a novel strategy to inhibit cancer cell proliferation by
turning off the nutrient sufficiency signals.
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Figure 1.3: mTOR Coordinates Signals to Induce Anabolic Cell Growth and Proliferation. mTORC1
is composed of mTOR, Raptor, and mLST8 and exerts its effects mainly through its two downstream
effectors, ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1) in
response to nutrients (Sabatini, 2006). mTORC2 is composed of mTOR, Rictor, mSIN1 and mLST8, which
responds to growth factors and exerts its effects primarily through the phosphorylation of Akt (Sabatini,
2006).

Regulation of PLD
PLD catalyzes the hydrolysis of phosphatidylcholine, releasing the choline head group
and producing PA. There are two major isoforms of PLD in humans – PLD1 and PLD2,
each of which has distinct roles and subcellular localizations. PLD1 is found throughout
the cell, particularly in the Golgi, lysosome and perinuclear region (Oude Weernink et al.,
2007). PLD2 is mostly present at the plasma membrane and endosomes – playing a role

	
  

9	
  

in exocytosis, endocytosis and endosomal functions (Oude Weernink et al., 2007).
However, both isoforms have been shown to alter their localization in response to certain
conditions, indicating a significant role for PA in many cellular roles (Oude Weernink et
al., 2007). Several Ras GTPases are known to activate PLD1 in a GTP-dependent
manner (Luo et al., 1998). RalA, a Ras-related GTPase, has been indicated as a regulator
of PLD1 (Jiang et al., 1995). PLD1 is constitutively and directly associated to RalA and
upon activation, promotes the association between the Arf-family GTPases and PLD1 to
activate PLD activity (Luo et al., 1998) (Fig. 1.4). Of the 5 known isoforms of Arf, Arf1
and Arf 6 have been associated with PLD1, linking PLD/PA with membrane trafficking
and vesicle transport. PLD1 is also activated by Rheb, which is downstream of PI 3kinase (PI3K) and is required for activation of mTOR (Sun et al., 2008).
Our lab has previously shown that elevated PLD activity seen in many human
cancers is dependent upon the presence of EAA (lysine, leucine, and arginine), and
glucose (Xu et al., 2011) (Fig. 1.4A). Likewise, PLD activity is necessary for mTORC1
stimulation by EAA and glucuose (Xu et al., 2011) (Fig. 1.4B). Both PLD and mTORC1
activity in response to amino acids and glucose were dependent on RalA and Arf6, as
well as the Class III PI3K, human Vacuolar protein sorting 34 (hVps34) (Fig. 1.4C).
hVps34 generates PI 3-phosphate (PI3P), which recruits proteins with Phox (PX)
domains, namely PLD1 and PLD2 (Xu et al., 2011). Following this study, Yoon et al.
showed that amino acids induce translocation of PLD1 to the lysosome in a hVps34depdenent manner, where it activates mTORC1 (Yoon et al., 2011) (Fig. 1.4C).
Interestingly, the hVps34-PLD1 pathway acts independently, yet in parallel, to the Rag
pathway of amino acid-induced mTORC1 activation (Yoon et al., 2011) (Fig. 1.4C).
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Figure 1.4: Amino Acid Sensing by mTORC1. (A) PLD activity requires essential amino acids (Lys,
Leu, Arg) (Figure from: Xu et al., 2011). (B) PLD activity is required for amino acid-induced activation of
mTORC1 (Figure from: Xu et al., 2011). (C) Amino acid-mediated mTORC1 signaling occurs by two
separate, but parallel mechanisms (Wiczer and Thomas, 2012).

Rationale
Previous studies have identified two different mechanisms for mTORC1 activation by
glutamine – one that is Rag-dependent, whereby the production of αKG from glutamine
stimulates Rag GTPase activation (Durán et al., 2012), and one that is Rag-independent
and Arf1-dependent (Jewell et al., 2015). It is unclear whether the Rag-independent
mechanism relies on the amino acid itself, or the metabolism of glutamine. Additionally,
Arf1 has previously been identified as necessary for amino acid-induced activation of
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mTORC1 in an indirect manner (Li et al., 2010). Arf6 has also been indicated as vital for
mTORC1 activation, with Arf6 being required for mTORC1 stimulation by EAA and
glucose (Ma et al., 2010; Xu et al., 2011). Importantly, the Arf GTPase family has been
implicated in regulating PLD activity via recruitment of Arf into the complex consisting
of PLD1 and RalA (Kim et al., 1998; Luo et al., 1998).
Since PLD is regulated by the Arf GTPases, we hypothesized that PLD is
involved in glutamine-dependent mTORC1 activation in a Rag-independent manner. In
this study we provide evidence that PLD-derived PA is required for glutamine to activate
mTORC1, even in the absence of leucine or Rag A/B. This work describes a key
component, PLD, in the Rag-independent pathway of glutamine activation of mTORC1.
PLD possibly represents an important compensation mechanism for glutamine to keep
mTORC1 active even in the absence of EAA, particularly leucine, as well as an
explanation as to how mTORC1 localizes to the lysosome in the absence of the RagGTPases.

Significance
Rapamycin, the inhibitor of mTOR, interacts with mTOR in a manner competitive with
PA, thus, elevated PLD activity imparts rapamycin resistance (Foster, 2009). Clinical
trials using rapamycin treatments have been somewhat unsuccessful in part because high
PLD activity has been reported in nearly all cancers where it has been tested, providing
cancer cells with resistance against rapamycin (Foster, 2009). By studying rapamycin, we
have seen that it competes with PA, interrupts PA signaling to mTOR, inhibits activation
of mTOR complexes and decreases cell proliferation (Foster, 2009). This has led us to
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hypothesize that by decreasing the available PA we would be able to decrease cell
proliferation by deactivating mTOR signaling, in a manner analogous to that of
rapamycin. This will allow new therapeutics that target the PA-mTOR signaling pathway
to be developed that target a larger number of cancers and evade the rapamycin resistance
imparted by PLD.
Glutamine is an extremely vital nutrient to a growing and dividing cell and
therefore, cancer cells acquire an addiction to glutamine to sustain their increased cell
proliferation. Our lab has reported that after the early G1 growth factor restriction
checkpoint of the mammalian cell cycle, the late G1-phase of the cell cycle contains a
series of metabolic checkpoints mediated by mTOR, EAA and glutamine (Saqcena et al.,
2013). Interestingly, each of these metabolic checkpoints are temporally distinct, with
mTOR occurring after both amino acid checkpoints (Saqcena et al., 2013). This data
indicates how important glutamine is as a nutrient source, in that it has its own
checkpoint, distinct from EAA.
We were interested in the glutamine-dependent regulation of PLD, as PLD
confers many survival signals in cancer cells. PLD activity has been shown to confer
resistance to apoptosis under serum-starved conditions in Ras-driven cells, indicating that
activation of PLD is necessary for survival in these cancer cells (Shi et al., 2007). PLD
activity has been shown to confer survival in breast cancer cell lines by inducing the
expression of Myc and suppressing stress-induced apoptosis (Rodrik et al., 2005). Thus,
targeting PLD survival signals may represent an effective strategy to induce cell death by
interfering with the impending survival signals produced by PLD activation.
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Moreover, inhibition of PLD may prove to be an effective strategy of controlling
glutamine-addicted cancers. Since glutamine has proved to be such a crucial nutrient for
cancer cell growth, many new cancer therapeutic studies have been aimed at exploiting
glutamine sensitivities using many different inhibitors. There is rationale for the
utilization of anaplerotic inhibitors (Wise and Thompson, 2010); however, some studies
have not indicated glutaminolysis as always required to stimulate mTOR (Nicklin et al.,
2009), indicating that these drugs may not be the best therapeutic strategy. On the other
hand, blocking glutamine-dependent mTORC1 activation using inhibitors of SLC7A5
may be more efficacious. However, this relies on the leucine-dependency of mTORC1,
rather than the direct effect of glutamine. The work described in this study has further
elucidated the mechanism of glutamine regulation of PLD to help direct more efficacious
ways to how to control glutamine-addicted cancer growth. Ultimately, this study has
provided further rationale for PLD inhibitors to be utilized therapeutically in glutamineaddicted cancers.
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CHAPTER 2: RESULTS
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PLD Activity is Required for mTORC1 Activation by Glutamine
It is known that glutamine is required for mTORC1 activation (Durán et al., 2012; Jewell
et al., 2015; Nicklin et al., 2009). Previous work from our lab has indicated that PLD
activity is required for mTORC1 activation by other nutrients, notably EAA, and glucose
(Xu et al., 2011). The nutrient-responsive role of PLD has led us to hypothesize that PLD
activity is required for glutamine to stimulate mTORC1. To test this, we used two K-Ras
driven cancer cells: MDA-MB-231 and Calu-1, which are known to have elevated PLD
activity (Shi et al., 2007). The MDA-MB-231 and Calu-1 cells were deprived of
glutamine for 24 hours, and then re-fed glutamine for 1 hour to re-stimulate mTORC1 in
the presence of inhibitors against the two PLD isoforms, PLD1 and PLD2, or DMSO
vehicle control. To measure mTORC1 activation we looked at phosphorylation of the
mTORC1 substrate ribosomal protein p70-S6 kinase (p70S6K) at Thr389. As shown in
Fig. 2.1A, PLD inhibitors effectively blocked phosphorylation of S6K in both cell lines,
indicating that PLD activity is required for glutamine to stimulate mTORC1 (Fig. 2.1A).
We next used 1-butanol (1-BtOH) to inhibit PA-production via PLD. 1-BtOH acts as a
more efficient nucleophile than water for PLD to use as a substrate, and as a result, PLD
will produce phosphatidylbutanol at the expense of PA (Zheng et al., 2006). 1-BtOH
blocked phosphorylation of S6K in response to glutamine even more effectively than
PLD inhibitors in MDA-MB-231 and Calu-1 cells (Fig. 2.1B), an effect seen previously
in response to essential amino acids and glucose (Xu et al., 2011). Tertiary-butanol (tBtOH), which is not an effective substrate for PLD, was used as a negative control and
did not block glutamine-dependent mTORC1 activation in either cell line (Fig. 2.1B).
These data indicate that mTORC1 activation by glutamine is dependent on PLD activity.
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We next examined the effect of glutamine deprivation on PLD activity. MDAMB-231 and Calu-1 cells were deprived of glutamine for 24 hours, and the levels of PLD
activity were determined relative to cells supplied with glutamine. As shown in Fig. 2.1C,
glutamine deprivation reduced the level of PLD activity in both the MDA-MB-231 and
Calu-1 cells by 60% and 40%, respectively. These data indicate that a substantial amount
of cellular PLD activity is dependent on the presence of glutamine. To further establish a
role for PLD and PA in the activation of mTOR by glutamine, we investigated whether
mTORC1 activation following glutamine deprivation could be rescued with exogenously
supplied PA. We used 1-palmitoyl-2-oleoyl-PA, which we have previously reported
activates mTORC1 and mTORC2 following serum withdrawal (Menon et al., 2017;
Toschi et al., 2009). Likewise, Jie Chen and colleagues have reported that PA with at
least one mono-unsaturated fatty acid activates mTORC1 (Yoon et al., 2015). As shown
in Fig. 2.1D, PA rescued S6K phosphorylation in both MDA-MB-231 and Calu-1 cells.
Collectively, the data in Fig. 2.1 reveal a role for PLD-derived PA in the activation of
mTORC1 in response to glutamine.
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Figure 2.1: Glutamine-Induced Activation of mTORC1 is Dependent on PLD-Derived PA. (A) MDAMB-231 cells and Calu-1 cells were plated in 6-well plates at 60% confluence in complete medium (CM)
containing 10% fetal bovine serum (FBS) overnight. The cells were then shifted to either fresh CM
containing 10% dialyzed FBS (DFBS) and 8 mM glutamine (Gln), or Gln-free media supplemented with
10% DFBS for the last 24 h of the experiment. Cells were re-fed with 8 mM Gln for 1 h in the presence or
absence of 10 µM PLD1 and 10 µM PLD2 inhibitors (PLDi). All control wells were given DMSO. Lysates
were analyzed for phosphorylated mTORC1 substrate p70S6K at Thr389 (herein referred to as P-p70S6K) by
Western blot. (B) MDA-MB-231 and Calu-1 cells were plated as in (A), starved of Gln for 24 h, and re-fed
with 8 mM Gln for 1 h in the absence or presence of 0.8% t-BtOH or 0.8% 1-BtOH and collected for
Western blot. (C) MDA-MB-231 cells (n=5) and Calu-1 cells (n=4) were plated as in (A). The following
day, cells were shifted to fresh media with 8 mM Gln (CM) or without Gln (-Gln) for 24 h. Cells were then
harvested and analyzed for PLD activity, as described in the methods section. Relative PLD activity values
are normalized to CM sample, which has been given a value of 100%. Significance asterisks are in
comparison to CM sample. Data are represented as mean ± SD. ***P<0.001; ****P<0.0001. (D) MDAMB-231 and Calu-1 cells were plated as in (A) and then shifted to either fresh CM containing 8 mM Gln
and 10% DFBS, or Gln-free DMEM containing 10% DFBS for 24 h. Cells were then given with two doses
of 300 µM palmitoyl-oleoyl-phosphatidic acid (PA) at 30 min time intervals. Cells were then collected for
Western blot. All Western blot images in (A), (B), and (D) are representative of at least 3 independent
experiments.
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Glutamine Activation of PLD and mTORC1 Occurs Independently of Leucine
Murphy and colleagues previously showed that glutamine uptake and subsequent efflux
through SLC7A5/SLC3A2 in exchange for leucine influx is necessary for mTORC1
activation (Fig. 2.2A) (Nicklin et al., 2009). This work showed that leucine does not
stimulate mTORC1 in the absence of glutamine. We therefore wanted to determine
whether the PLD-dependent induction of mTORC1 was dependent on leucine. Consistent
with work by Murphy and colleagues (Nicklin et al., 2009), leucine stimulated p70S6K
phosphorylation in MDA-MB-231 cells strongly in the presence of glutamine, whereas in
the absence of glutamine, leucine had only a modest effect on p70S6K phosphorylation
(Fig. 2.2B, compare lanes 2 and 3 with lanes 6 and 7). However, glutamine was able to
stimulate mTORC1 in both the presence and absence of leucine (Fig. 2.2B, lanes 5 and 8)
– indicating that glutamine has its own mechanism to stimulate mTORC1 independent of
leucine. Additionally, leucine and glutamine synergized to activate mTORC1 to a much
fuller extent, with levels of P-p70S6K even higher than that of the control lane (Fig. 2.2B,
lanes 1 and 9).
We next examined the effect of leucine and glutamine deprivation on PLD
activity. When cells were deprived of only leucine, PLD activity was modestly
decreased, whereas glutamine deprivation resulted in a much stronger decrease in PLD
activity (Fig. 2.2C). No further decrease in PLD activity was observed upon deprivation
of both glutamine and leucine (Fig. 2.2C). Thus, glutamine has a more significant role in
regulating PLD activity than leucine. We also examined the effect of leucine and
glutamine stimulation on PLD activity. Consistent with data from Murphy and colleagues
where the activation of mTORC1 by leucine was dependent on glutamine (Nicklin et al.,
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2009) and our data in Fig. 2.2B, leucine did not significantly stimulate PLD activity in
the absence of glutamine (Fig. 2.2D). In contrast, glutamine activated PLD in in the
absence of leucine (Fig. 2.2D). Treating with leucine and glutamine simultaneously
produced a somewhat larger increase in PLD activity (Fig 2.2D). The further increase in
PLD activity and mTORC1 activation with both leucine and glutamine is likely due to reactivation of the antiporter system (Fig. 2.2A), bringing leucine into the cell to further
activate mTORC1. Collectively, the data in Fig. 2.2 further demonstrate a role for PLD in
the glutamine induction of mTORC1 and establish that the effect of leucine on both
mTORC1 and PLD activity is dependent on glutamine.
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Figure 2.2: Glutamine Stimulates mTORC1 and PLD in a Leucine-Independent Manner. (A)
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Schematic model showing the exchange of Gln for Leu through the bi-directional transporter,
SLC7A5/SLC3A2. (B) MDA-MB-231 cells were plated in 6-well plates at 60% confluence in CM
containing 10% FBS overnight. The following day, cells were shifted to either fresh DMEM containing 8
mM Gln and 0.8 mM Leu (CM), leucine-free DMEM (-Leu), Gln-free DMEM (-Gln), or DMEM lacking
both Leu and Gln (-Leu/-Gln) for 24 h. All wells contained 10% DFBS. Cells were re-fed 8 mM Gln and/or
0.8 mM Leu for 1 h and analyzed by Western blot. Image shown is representative of at least 3 independent
experiments. (C) MDA-MB-231 cells were plated and shifted to CM (n=6), -Leu (n=6), -Gln (n=3), or Leu/-Gln (n=5), for 24 h, as in (B), at which point cells were harvested and collected for a PLD activity
assay. Relative PLD activity levels are normalized to the CM sample (first column), which has been given a
value of 100%. Significance asterisks are in comparison to this first column. (D) MDA-MB-231 cells were
plated as in (B) and then shifted to Leu and Gln-free DMEM containing with 10% DFBS for 24 h, and then
re-fed with either Leu (n=5), Gln (n=4), or Leu and Gln (n=5) together for 1 h. The cells were then
harvested and analyzed for PLD activity. Relative PLD activity levels are normalized to the –Leu/-Gln
sample (n=5) without any re-feed (first column), which has been given a value of 100%, and significance
asterisks are in comparison to this first column. All relative PLD activity values in (C) and (D) are
displayed as mean ± SD. *P<0.05; **P<0.01; ****P<0.0001.

Arf1, RalA, and Rheb are Required for Glutamine to Stimulate mTORC1 in a PADependent Manner
Guan and colleagues previously reported that although all other amino acids require the
Rag GTPases to activate mTORC1, glutamine does not (Jewell et al., 2015). Intriguingly,
the activation of mTORC1 by glutamine was dependent on the GTPase Arf1 (Jewell et
al., 2015). Since several Arf GTPases have been implicated as activators of PLD activity
(Kim et al., 1998; Luo et al., 1998; Luo et al., 1997; Xu et al., 2011), we hypothesized
that Arf1-dependent mTORC1 activation is dependent on PLD activity. As expected,
knockdown of Arf1 decreased PLD activity in MDA-MB-231 cells (Fig. 2.3A). Further,
knockdown of Arf1 resulted in a block of glutamine-dependent mTORC1 activation, as
reported previously (Jewell et al., 2015) (Fig. 2.3B, left panel). Exogenously supplied PA
rescued the phosphorylation of S6K caused by Arf1 inhibition – indicating that PA
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production is downstream of glutamine-Arf1 signaling (Fig. 2.3B, left panel). The same
effect was seen in the absence of leucine, indicating that this pathway is active even in
the absence of leucine (Fig. 2.3B, right panel). This suggests that the Arf1-PLD pathway
is a parallel pathway that can remain active even in the absence of EAA, like leucine.
As we have previously shown that Arf6 is required for PLD activity and
mTORC1 activation in response to EAA and glucose (Xu et al., 2011), we investigated
whether Arf6 is required for glutamine-induced mTORC1 activation. siRNA-mediated
knockdown of Arf6 did not result in a decrease in PLD activity in MDA-MB-231 cells
(Fig. 2.3A) and only modestly decreased mTORC1 activation in response to glutamine in
the presence of leucine (Fig. 2.3C, left panel). However, in the absence of leucine, Arf6
knockdown slightly blocked glutamine-dependent phosphorylation of p70S6K, but was not
rescued with PA addition (Fig. 2.3C, right panel). The inhibition of mTORC1 activation
produced from knockdown of Arf6 was not nearly as strong as that from the knockdown
of Arf1, and since Arf6 knockdown did not affect basal levels of PLD activity and could
not be rescued with PA, this suggests that this was not due to Arf6-dependent PLD
activity. Thus, Arf6 is not required for glutamine-induced mTORC1 activation. This
represents a differential utilization of Arf GTPases for PLD/mTORC1 activation in
response to different nutrient sources.
It has previously been reported that another small GTPase, RalA, can promote
Arf1-dependent PLD activity by direct interaction with PLD1 (Kim et al., 1998).
Similarly, we reported that upon activation with GTP, RalA, which is constitutively
bound to PLD1, recruits Arf GTPases to enhance PLD activity (Luo et al., 1998). We
therefore examined whether RalA was required for the activation of mTORC1 by
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glutamine. Knockdown of RalA decreased PLD activity in MDA-MB-231 cells (Fig.
2.3D) and suppressed the glutamine induction of mTORC1 in the presence and absence
of leucine (Fig. 2.3E). This effect could be rescued with the addition of exogenous PA
(Fig. 2.3E) – indicating that PA production via PLD is downstream of RalA.
We next looked into the dependency for Rheb in glutamine-induced mTORC1
activation. Rheb is typically required for mTORC1 activation at the lysosomal membrane
(Buerger et al., 2006). Further, Rheb associates with PLD in a GTP-dependent manner
(Sun et al., 2008). Indeed, we saw that siRNA-mediated knockdown of Rheb decreased
basal levels of PLD activity (Fig. 2.3F). Next, we found that in both the presence and
absence of leucine, knockdown of Rheb blocked glutamine induction of phosphorylation
of S6K, and thus, mTORC1 activation (Fig. 2.3G). This effect was rescued with the
addition of exogenous PA, indicating that PLD activation is downstream of Rheb (Fig.
2.3G). This data indicate that while Rheb is required for the activation of mTORC1 by
glutamine, PLD lies downstream of Rheb, playing a role in this activation. Taken
altogether, the data in Fig. 2.3 identifies Arf1, RalA, and Rheb GTPases as crucial
players in activating PLD for the subsequent activation of mTORC1.
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Figure 2.3: Glutamine Stimulates mTORC1 and PLD in an Arf1/RalA/Rheb-Dependent Manner. (A)
MDA-MB-231 cells plated in 6-well plates at 40% confluence in CM supplemented with 10% FBS. The
following day, cells were transfected either with a control (ctrl, n=4), Arf1 (n=4), or Arf6 (n=4) siRNA.
After 72 h, cells were harvested and collected for a PLD activity assay. (B) MDA-MB-231 cells were
plated and transfected with ctrl or Arf1 siRNA, as in (A). For the last 24 h of the experiment, cells were
starved of either Gln (-Gln, left panel) or both Leu and Gln (-Leu/-Gln, right panel). Cells were re-fed Gln
for 1 h in the absence or presence of PA (two doses of 300 µM PA at 30 min intervals). Cells were then
collected and analyzed by Western blot. (C) MDA-MB-231 cells were plated and transfected with ctrl or
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Arf6 siRNA, as in (A). Cells were shifted to -Gln DMEM (left panel) or -Leu/-Gln DMEM (right panel) for
the last 24 h of the experiment. Cells were re-fed Gln for 1 h in the presence or absence of PA, as in (B).
Cells were then collected and analyzed by Western blot. (D) MDA-MB-231 cells plated in 6-well plates at
40% confluence in CM supplemented with 10% FBS. The following day, cells were transfected either with
a control (n=4) or RalA (n=4) siRNA. After 48 h, cells were harvested and collected for a PLD activity
assay. (E) MDA-MB-231 cells were plated and transfected with ctrl or RalA siRNA, as in (D). Cells were
shifted to -Gln media for 24 h, and re-fed Gln for 1 h in the absence or presence of PA, as in (B). Cells
were then collected and analyzed by Western blot. (F) MDA-MB-231 cells plated in 6-well plates at 40%
confluence in CM supplemented with 10% FBS. The following day, cells were transfected either with a ctrl
(n=3) or Rheb (n=3) siRNA. After 48 h, cells were harvested and collected for a PLD activity assay. (G)
MDA-MB-231 cells were plated and transfected with ctrl or Rheb siRNA, as in (D). Cells were shifted to Gln media for 24 h and re-fed Gln for 1 h in the absence or presence of PA, as in (B). Cells were then
collected and analyzed by Western blot. All Western blot images in (B), (C), (E), and (G) are representative
of 3 independent experiments. All PLD activity values in (A), (D), and (F) are normalized to the ctrl siRNA
sample, which has been given a value of 100%, and significance asterisks are in comparison to the ctrl
sample. Relative PLD activity is represented as mean ± SD. Not significant (ns) p>0.05; *P<0.05;
**P<0.01; ***P<0.005.

Glutamine Activates mTORC1 via PLD Independently of the Rag GTPases
While Rheb is required for activation of mTORC1 at lysosomes, the Rag GTPases are
thought to recruit mTORC1 to the lysosomal membrane in response to amino acids,
whereby Rheb can activate mTORC1. However, while Guan and colleagues reported that
glutamine does not require the Rag GTPases for the lysosomal localization or activation
of mTORC1 (Jewell et al., 2015), Hall and colleagues have shown that glutamine and
leucine activate mTORC1 via αKG production upstream of the Rag GTPases (Durán et
al., 2012). We were therefore interested in understanding the interplay of the two
pathways — Rag-independent and Rag-dependent — that glutamine uses to activate
mTORC1. We hypothesized that if the Rag-dependent and Rag-independent pathways
work in parallel, then the absence of RagA/B results in the activation of a compensatory
pathway dependent on Arf1 and PLD activity. Using HEK293A control or HEK293A
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RagA/B knockout (KO) cell line previously described (Jewell et al., 2015), we found that
the RagA/B KO cell line had elevated basal PLD activity as compared to control
HEK293A cells (Fig. 2.4A). This data suggests that PLD compensates and increases its
production of PA in the absence of the Rag GTPases to allow glutamine to keep
mTORC1 active. Furthermore, as shown in Fig. 2.4B, PA was still able to rescue
phosphorylation of S6K in the absence of glutamine in the Rag A/B KO cells, indicating
that PA does not require RagA/B to stimulate mTORC1 (Fig. 2.4B).
Since it has previously been reported that glutamine exerts much of its effects to
mTORC1 via production of αKG, which goes on to stimulate mTORC1 via GTP-loading
and activation of the RagB GTPase (Durán et al., 2012), we next wanted to see if αKG
requires the presence of the Rag GTPases to activate mTORC1. We added dimethyl-αKG
(DMαKG), a cell permeable form of αKG, to the HEK293A control and RagA/B KO
cells to see if it could rescue mTORC1 activation following 24 hours of glutamine
deprivation – even in the absence of the Rag’s. We were surprised to see that DMαKG
was able to activate mTORC1 in both control and Rag A/B KO HEK293A cells (Fig.
2.4C). This data indicates that while αKG can activate Rag B (Durán et al., 2012), αKG
does not require the presence of RagA/B to stimulate mTORC1 (Fig. 2.4C). Together, the
data shown in Fig. 2.4 suggests that the PLD/PA signaling pathway is separate, but
parallel to the Rag pathway for glutamine-dependent mTORC1 activation, and
compensates upon inhibition of the Rag GTPases. Furthermore, this data suggests that
αKG also plays a role in this parallel, PLD-dependent pathway.
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Figure 2.4: Glutamine Stimulates mTORC1 in a Rag-Independent Manner Via Elevated PLD
Activity. (A) HEK293A control (n=5) and RagA/B KO (n=5) cells were plated at 70% confluence in CM
supplemented with 10% FBS. The following day, cells were harvested and analyzed for basal PLD activity
levels. Relative PLD activity values are normalized to the control sample, which has been given a value of
100%. Significance asterisks are in comparison to the control sample. Data are represented as mean ± SD.
****P<0.0001. (B) HEK293A control and RagA/B KO cells were plated in 6-well plates at 60%
confluence in CM containing 10% FBS. The following day, cells were shifted to Gln-free media
supplemented with 10% DFBS (-Gln) for the last 24 h of the experiment and re-fed with with two doses of
300 µM PA at 30 min intervals, and then collected for Western blot. (C) HEK293A control and RagA/B
KO cells were plated in 6-well plates at 60% confluence in CM containing 10% FBS. The following day,
cells were shifted to either fresh DMEM containing 8 mM Gln and 10% DFBS (CM), or glutamine-free
DMEM supplemented with 10% DFBS for the last 24 h of the experiment. Cells were re-fed with 4 mM
DMαKG for the last 2 h of the experiment. Lysates were analyzed by Western blot. All Western blot images
in (B) and (C) are representative of 3 independent experiments.

αKG Stimulates mTORC1 in a PLD/PA-dependent Manner
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It remains unclear if the Arf1-mediated pathway of Gln-dependent mTORC1 activation
requires glutamine itself, or a downstream metabolite of glutamine, such as αKG (Jewell
et al., 2015). However, the data in Fig. 2.4C suggests that αKG must activate mTORC1 in
a manner that does not require the Rag GTPases. Thus, we next looked to see if αKG was
able to stimulate mTORC1 in the absence of PLD. As shown in Fig. 2.5B, we found that
DMαKG stimulation of mTORC1 was blocked by 1-butanol treatment (Fig. 2.5B),
indicating that PLD-derived PA is required for αKG to activate mTORC1. Additionally,
knockdown of Arf1 blocked DMαKG from activating mTORC1 and phosphorylating
S6K, indicating that Arf1 is also required for activation of mTORC1 by αKG (Fig. 2.5C).
Taken together, these data indicate that αKG does not require RagA/B to activate
mTORC1, and can instead utilize the Arf1/PLD signaling pathway for mTORC1
activation.
Glutamate derived from glutamine can be converted into αKG via GDH or GOT
(Fig. 2.5A). Since GDH is allosterically activated by leucine (Gleason et al., 2007), we
hypothesized that the PLD pathway, which occurs independently of leucine, involves
αKG production via GOT, rather than GDH. Interestingly, we found that both
knockdown of either GOT or GDH blocked glutamine from activating mTORC1 (Fig.
2.5D), indicating that either enzyme can be utilized for αKG production from glutamine
and the subsequent activation of mTORC1 (Fig. 2.5D). Furthermore, the dependence on
either enzyme did not change in the absence of leucine (Fig. 2.5D). PA was able to rescue
the effects of knocking down both GOT or GDH in the presence and absence of leucine,
indicating that PA production lies downstream of αKG production (Fig. 2.5D).
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While GDH results in the production of αKG, with ammonia as a byproduct, GOT
results in the production of aspartate as well. Aspartate has been identified as an essential
nutrient for K-Ras driven cancer cell growth (Son et al., 2013) and cell cycle progression
through S-phase following glutamine deprivation (Patel et al., 2016; Son et al., 2013).
While we have already shown that αKG can rescue mTORC1 activation following
glutamine deprivation, we next wanted to see if aspartate could as well. In fact, L-aspartic
acid β-methyl ester hydrochloride (βMD), a cell permeable analog of aspartate, was
incapable of rescuing phosphorylation of S6K (Figs. 2.5E and 2.5F). This was the case
both in the presence or absence of leucine and indicates that while GOT is required for
production of αKG for mTORC1 activation, the production of aspartate is not required
for mTORC1. This is interesting, and may imply a specific role for aspartate in cell
survival (Patel et al., 2016; Son et al., 2013), rather than mTORC1 activation.

	
  

29	
  

A"

B"

Gln" Leu"

DMαKG&&
t(BtOH&
1(BtOH&

Extracellular& SLC7A5/
SLC3A2"
Gln" Leu"

D"

(Gln,&24&h&
+"
$"
$"

+"
$"
$"

+"
+"
$"

+"
$"
+"

Ac/n"

GOT$ GDH$
NH3"
Asp"
αKG"

$"
$"
$"

$"
$"
$"

p70S6K"

Glu"

DMαKG&&
Arf1&siRNA&
PA&
S6K
P$p70 "

$"
$"
$"

P$p70S6K"

GLS$

C"

(Gln,&24&h&

CM&

+"
+"
$"

siRNA:&
Gln&(1&h)&
PA&

+"
+"
+"

(Leu/(Gln,&24&h&

(Gln,&24&h&
Ctrl& GOT1/2& GDH1&

Ctrl& GOT1/2& GDH1&

$
$

$
$

+ + + + +
$ $ + $ +

+ + + + +
$ $ + $ +

P$p70S6K"

p70S6K"

p70S6K"

Arf1"

GOT1"
GOT2"

Ac/n"

GDH1"
Ac/n"

E"
(Gln,&24&h&
DMαKG&&
βMD&

$" + $" +
$" $" + +

(Leu/(Gln,&24&h&
$
$

+ $ +
$ + +

F"

CM&
βMD&(mM)&
Gln&(1&h)&

P$p70S6K"

P$p70S6K"

p70S6K"

p70S6K"

Ac/n"

Ac/n"

(Gln,&24&h&

$" $" 5" 10" 14" $"
$" $" $" $" $" +

Figure 2.5: PLD/Arf1, But Not RagA/B, Are Required for αKG to Activate mTORC1. (A) Schematic
of αKG production from Gln. Briefly, Gln is converted to glutamate (Glu) via GLS. Glutamate can be
converted to αKG via GOT with the concomitant production of Aspartate (Asp) or via GDH, which is
allosterically activated by Leu. Leu is brought into the cell in exchange for Gln via SLC7A5/SLC3A2. (B)
MDA-MB-231 cells were plated in 6-well plates at 60% confluence in CM containing 10% FBS overnight.
The cells were then shifted to either fresh DMEM with 8 mM Gln and 10% DFBS (CM), or glutamine-free
media supplemented with 10% DFBS for the last 24 h of the experiment and re-fed with 4 mM DMαKG
for 2 h in the presence of either 0.8% t-BtOH, or 0.8% 1-BtOH. Lysates were analyzed by Western blot.
(C) MDA-MB-231 cells were plated in 6-well plates at 40% confluence in CM containing 10% FBS
overnight. The following day, cells were transfected either with control or Arf1 siRNA for a total of 72 h,
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as in Fig. 3A. For the last 24 h of the experiment, cells were starved of Gln and then re-fed with DMαKG
for 2 h in the absence or presence of PA (two doses of 300 µM PA at 30 min intervals). Cells were then
collected and lysates were analyzed by Western blot. (D) MDA-MB-231 cells were plated in 6-well plates
at 40% confluence in CM containing 10% FBS. The following day, cells were transfected either with a ctrl,
GOT1/2, or GDH1 siRNA for a total of 72 h. For the last 24 h of the experiment, cells were starved of Gln
(-Gln, left panel) or both Leu and Gln (-Leu/-Gln, right panel). Cells were re-fed Gln for 1 h in the absence
or presence of PA as in (C). Cells were then collected and analyzed by Western blot. (E) MDA-MB-231
cells were plated in 6-well plates at 60% confluence in CM containing 10% FBS overnight. The cells were
then shifted to either Gln-free media (-Gln, left) or Leu and Gln-free media (-Leu/-Gln), both supplemented
with 10% DFBS, for 24 hours. Cells were then re-fed with either 4 mM DMαKG or 10 mM βMD 2 h, or 8
mM Gln for 1 h. Cells were then collected and lysates were analyzed by Western blot. (F) MDA-MB-231
cells were plated in 6-well plates at 60% confluence in CM containing 10% FBS overnight. The cells were
then shifted to Gln-free media (-Gln) supplemented with 10% DFBS, for 24 hours. Cells were then re-fed
with indicated concentrations of βMD for 2 h, or 8 mM Gln for 1 h. Cells were then collected and lysates
were analyzed by Western blot. All Western blot images in (B), (C), (D), (E), and (F) are representative of
at least 3 independent experiments.
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CHAPTER 3: DISCUSSION
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While much is known about how glutamine stimulates mTORC1, there remain several
gaps in the previously described pathways, as well as the interplay between those
pathways. In this report, we have provided evidence that PLD activity is required for
glutamine to activate mTORC1. This pathway involves Arf1 for the activation of PLD
(Fig. 2.3A-B), which is consistent with work from Guan and colleagues identifying an
Arf1 requirement in the Rag-independent mechanism by which glutamine activates
mTORC1 (Jewell et al., 2015). Furthermore, we have also shown that PLD acts
independently of the Rag GTPase’s, in that PA can stimulate mTORC1 even in the
absence of RagA/B (Fig. 2.4B). Intriguingly, we saw that RagA/B knockout cells display
elevated basal levels of PLD activity (Fig. 2.4A), suggesting that PLD represents a
compensatory pathway for glutamine to activate mTORC1 by an alternate pathway.
While all other amino acids require the Rag’s for lysosomal localization and the
subsequent activation of mTORC1, glutamine does not (Jewell et al., 2015). The work in
our report demonstrates that glutamine utilizes PLD even in the absence of the EAA,
leucine (Fig. 2.2). It has previously been thought that glutamine plays a large role in
activating mTORC1 through its own efflux to bring leucine, a potent mTORC1 activator,
into the cell (Nicklin et al., 2009). However, the pathway described here demonstrates a
more direct mechanism by which glutamine can activate mTORC1 even in the absence of
leucine, or the traditional amino acid-induced Rag GTPase machinery.
In addition to the requirement for Arf1, we have shown that RalA, another
GTPase, is also required for the activation of PLD, and the subsequent activation of
mTORC1. It has previously been reported that RalA is constitutively associated with
PLD and upon activation by Ras-signaling cascades, recruits Arf for the activation of
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PLD and production of PA (Luo et al., 1998; Luo et al., 1997). While knocking down
RalA did not produce a very strong decrease in basal levels of PLD activity (Fig. 2.3C),
we have previously shown that RalA knockdown is sufficient to block serum-deprivation
induced increases in PLD activity (Xu et al., 2011). Knockdown of either RalA or Arf1
blocked glutamine from inducing mTORC1 activity, and exogenously supplied PA
rescued both of these effects (Fig. 2.3B, 2.3E). Intriguingly, we have shown that another
Arf isoform, Arf6, was not required for glutamine to activate mTORC1 (Fig. 2.3C). We
had previously shown that Arf6, but not Arf1, was required for EAA and glucosedependent mTORC1 activation (Xu et al., 2011). These data indicate a differential Arf
requirement for Arf-dependent mTORC1 activation in response to distinct nutrient
sources. Interestingly, RalA, Arf1, and PLD are all enzymes involved in vesicle
trafficking (Gentry et al., 2014; Jackson and Bouvet, 2014; Roth, 2008). This may
support a role for these three enzymes in helping to localize mTORC1 to the lysosome in
the absence of the Rag GTPase’s, whereby mTORC1 can become activated by Rheb,
which is also required in this pathway (Fig. 2.3G).
Overall, we have reinforced the idea that glutamine does not require the
traditional Rag GTPase amino acid-signaling machinery to activate mTORC1. While it
remains unclear exactly what signal is driving mTORC1 to the lysosome in the absence
of the Rag’s, we have provided evidence for the requirement of the vesicle trafficking
enzymes PLD, Arf1 and RalA. There was also a dependence on Rheb for the glutamineinduced activation of mTORC1. Rheb has previously been shown to bind and activate
PLD in a GTP-dependent manner (Sun et al., 2008). It is conceivable that the RalA-Arfdependent PLD activity is driving mTOR to the lysosomal membrane where the

	
  

34	
  

activation of PLD activity shifts from Arf1 to Rheb. PA production is required for
stabilizing the mTOR-Raptor complex (Toschi et al., 2009) for its subsequent activation
and phosphorylation of p70S6K.
Murphy and colleagues have suggested that glutamine-derived αKG stimulates
activation of RagB and the subsequent activation of mTORC1 (Nicklin et al., 2009).
However, it was unclear if the Rag-independent pathway described by Guan and
colleagues involved glutamine itself, or a downstream metabolite of glutamine (Jewell et
al., 2015). In this report we have shown that αKG does not require the Rag GTPase’s, and
is capable of activating mTORC1 even in RagA/B KO cells (Fig. 2.4C). Furthermore, our
data in Fig. 5 indicate that αKG requires Arf1 and PLD, to activate mTORC1 (Fig. 2.5BC). Blocking the production of αKG from glutamine by knocking down either GDH or
GOT resulted in a block of mTORC1 activation that could be rescued by PA (Fig. 2.5D).
This was interesting, as we expected that due to the leucine-independence of the pathway,
the GOT reaction would be favorable, as leucine allosterically activates GDH (Gleason et
al., 2007) and stimulates glutaminolysis (Nicklin et al., 2009). Furthermore, we utilized
K-Ras-driven cancer cells for these experiments, which have previously been thought to
depend more on GOT for survival (Son et al., 2013). Nonetheless, knockdown of GDH
also inhibited mTORC1, and thus, still retained a role in producing αKG for mTORC1
activation in the absence of leucine, suggesting that αKG production is more important
for this activity, rather than the production of aspartate via GOT (Fig. 2.5D). Indeed,
while DMαKG activated mTORC1 following glutamine deprivation, the cell-permeable
aspartate analog, βMD, did not (Fig. 2.5E-F). We have previously shown that K-Ras cells
arrest in S-phase upon glutamine deprivation and that aspartate, but not αKG, could
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rescue the arrest (Patel et al., 2016) - suggesting that while aspartate production by GOT
is required for the K-Ras cancer cell survival (Son et al., 2013) and cell cycle progression
(Patel et al., 2016), there is a differential utilization of αKG for mTORC1 activation (Fig.
2.5). While it remains unclear how αKG is activating Arf1/RalA/PLD signaling, αKG is
at the center of cellular metabolism, and represents a useful sensor of metabolic
sufficiency to activate mTORC1. Besides donating carbons for the citric acid cycle, αKG
serves as a co-factor for αKG-dependent dioxygenases such as prolyl hydroxylases
(Durán et al., 2013), as well as the several histone demethylases (Lu and Thompson,
2012). In fact, Gottlieb and colleagues previously shown that prolyl hydroxylases
respond to αKG levels to activate mTORC1 (Durán et al., 2013). Thus, there are several
αKG-sensors that could play a role in this pathway and further studies are warranted to
better understand this.
The work described in this report utilized the two K-Ras driven cell lines, MDAMB-231 and Calu-1. While these cell lines were chosen due to their elevated PLD
activity (Shi et al., 2007), K-Ras-driven cancer cells have also been shown to have higher
glutamine addictions than other cancer cells. K-Ras mutations have been associated with
elevated expression of SLC1A5, resulting in increased glutamine uptake (Toda et al.,
2017), as well as elevated expression of GOT (Son et al., 2013). The metabolic rewiring
of enzymes involved in glutamine metabolism results in K-Ras-driven cancer cells to be
even more glutamine-dependent than other cancer cells. While exploiting cancer’s
addiction to glucose has been utilized for years in the clinic (Hamanaka and Chandel,
2012), more recent data indicating cancer’s requirement for glutamine is leading to new
therapeutics to exploit glutamine-dependence (Mukhopadhyay et al., 2015; Saqcena et
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al., 2015; Wise and Thompson, 2010). The work shown here suggests that there may be a
connection between elevated PLD activity and increased glutamine addiction in K-Ras
cancers, providing rationale for targeting PLD to shut off glutamine signaling in the
hopes to decrease cancer proliferation. Our lab has previously shown that phospholipase
D activity is directly correlated with an increase in cancer aggressiveness (Shi et al.,
2007; Utter et al., 2018; Zheng et al., 2006). The significance of these findings lies in the
fact that suppression of the PA-mTOR signaling pathway, including suppression of PLD
activity in cancer cells, may be a novel strategy to control cancer cell proliferation,
particularly in glutamine-addicted cancers. Going forward, we hope to find that by
interfering with the glutamine-PLD axis, we may be capable of controlling cancer cell
proliferation. Recent literature suggests that tumor cell metabolism may be an Achilles’
heel for cancer cells (Hanahan and Weinberg, 2011). Thus, by controlling glutaminedependent increases in PLD activity, we have the potential to exploit tumor cell
metabolism and reveal novel therapeutic opportunities for controlling both PLD and
mTOR activity that is responsive to glutamine. While targeting mTOR has had very
limited success (Houghton, 2010) and mTOR knockout is embryonic lethal (Guertin et
al., 2006), PLD inhibitors seem to be well tolerated and PLD1/PLD2 knockout mice are
viable (Frohman, 2015). The involvement of PLD in the signals emanating from
glutamine to activate mTORC1 represents a therapeutic opportunity for targeting
glutamine-addicted cancers.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
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As shown in the graphical summary in Fig. 3.1, the present study has demonstrated that
glutamine, and its’ downstream metabolite αKG, activate mTORC1 in a manner that
requires PLD activation and the subsequent production of PA. This pathway is dependent
on the GTPases, Arf1, RalA, and Rheb, for the activation of PLD and mTORC1. This
pathway occurs independently from the traditional amino acid-sensing machinery of the
Rag GTPases. The Rag GTPases are thought to recruit mTORC1 to the lysosome in
response to amino acids, whereby it can become activated by Rheb. However, in the
pathway described here, mTORC1 is still able to utilize Rheb for its’ activation in this
separate pathway. In fact, genetic ablation of the Rag A/B GTPases resulted in an
increase in basal levels of PLD activity, suggesting that this PLD pathway compensates
for the lack of the Rag GTPases. Furthermore, this pathway remains capable of activating
mTORC1 even in the absence of the EAA and potent mTORC1 activator, leucine.
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Fig. 3.1: Schematic model of Rag-Independent Glutamine Stimulation of mTORC1 via PLD-Derived
PA. Glutamine, which enters into the cell through SLC1A5, can be metabolized into αKG, through either
GOT or GDH in the presence or absence of leucine, to activate mTORC1. Although αKG has previously
been shown to activate mTORC1 by stimulating GTP-loading of Rag B for its subsequent activation
(Durán et al., 2012), in the present study, we have shown that αKG can activate mTORC1 independently of
Rag A/B. Instead, this pathway requires Arf1, RalA, Rheb, and PLD. PLD activation results in PA
production from phosphatidylcholine (PC). PA reactivates mTORC1 in the absence of glutamine and can
do so in the absence of Rag A/B. This pathway occurs independently of leucine, however, leucine can be
brought into the cell in exchange for glutamine via SLC7A5/SLC3A2, is a potent activator of Rag signaling
to mTORC1, and can stimulate glutaminolysis through the activation of GDH.
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While we have filled in several gaps of knowledge in this pathway, several
questions remain. It remains unclear how mTORC1 gets to the lysosome in the absence
of the Rag’s. Since Arf1, RalA and PLD are all involved in vesicle trafficking, we
postulate that RalA/Arf-depdendent PLD activity drives mTORC1 to the lysosomal
membrane in the absence of the Rag GTPases. There, Rheb can activate PLD and
produce the PA needed for the stabilization and subsequent activation of mTORC1.
However, this hypothesis remains to be tested and is currently under investigation by our
laboratory.
Furthermore, the data provided here indicate that αKG can activate mTORC1 via
this PLD-dependent pathway. However, it is unclear the mechanism and the role of αKG
in mTORC1 activation. Previous work has shown that αKG utilizes prolyl hydroxylases
to activate mTORC1 via the Rag GTPases, however, our pathway occurs independently
of the Rag GTPases. Likewise, αKG is known to be involved as a co-factor for histone
demethylases. Thus, both prolyl hydroxylases and histone demethylases represent
possible αKG-sensors. Moreover, αKG has roles as a carbon donor in the citric acid
cycle, and can contribute to several critical intermediary metabolites that may be sensed
in this pathway. Therefore, more work is warranted to understand how αKG influences
Arf1 and PLD.
Most importantly, it will be interesting to see the translational impact of this
work. While the work provided here has outlined more of the molecular basis for how
glutamine activates mTORC1, it remains unclear how glutamine affects cancer cell
growth via mTORC1. Several groups are working on how to target glutamine-addicted
cancers, so it will be interesting to see if PLD inhibition represents a therapeutic strategy
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to control these cancers, with minimal side effects. More work on how effective PLD
inhibitors are in minimizing K-Ras driven cancer growth can help to answer some of
these large-scale questions.
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CHAPTER 5: MATERIALS AND METHODS
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Antibodies and Reagents
Antibodies used were as follows: GDH1/2 (12793), P-Thr389-p70S6K (P-p70S6K) (9234),
p70S6K (9202), RagA (4357), RalA (3526), and Rheb (13879S) were obtained from Cell
Signaling; Actin (60008-1-Ig) from Proteintech Group; Arf1 (sc-53168), Arf6 (sc-7971),
GOT1/AATC (sc-46283), GOT2/AATM (sc-135181), and RagB (sc-169101) from Santa
Cruz. Ultima Gold scintillation fluid (6013681) and [3H]-myristic acid (NET830005MC)
were obtained from Perkin Elmer. PLD1 inhibitor (VU0359595) (857371), PLD2
inhibitor (VU0285655-1) (857372), 18:1 phosphatidylbutanol standard solution
(860203C), and 16:0-18:1 phosphatidic acid (POPA) (840857C) were obtained from
Avanti Polar Lipids, Inc. 1-Butanol (B7906) and tertiary-butanol (47172) were obtained
from Sigma Aldrich. Thin layer chromatography (TLC) plates (1.11798.0001) were
obtained from Millipore Sigma. DMSO (25-950-CQC) was obtained from Fisher
Scientific.

Cells and culture conditions
MDA-MB-231 breast and Calu-1 lung cancer cell lines were obtained from the American
Type Culture Collection. HEK293A control and RagA/B KO lines were a gift from the
Kun-Liang Guan laboratory and have been previously described (Jewell et al., 2015).
Calu-1 cells were cultured in McCoy’s 5A medium (Sigma M8403) containing 10% fetal
bovine serum (FBS) (F4135) and 4 mM L-glutamine (Sigma G7513). All other cells were
cultured in Dulbecco’s Modified Eagle’s Media (Sigma D6429) containing 10% FBS. All
culture media was supplemented with 1x antibiotic/antimycotic solution (Sigma A5955).
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Amino acid starvation experiments
All starvation experiments were done by rinsing the plates with Hank’s Balanced Salt
Solution (Sigma H9394) twice and then placing the appropriate starvation media in the
wells as follows: For Gln starvation, cells were placed in Gln-free DMEM (Sigma
D5546) or Gln-free McCoy’s 5A medium (for Calu-1 cells) (Sigma M8403)
supplemented with 10% dialyzed FBS (DFBS) (Sigma F0392) for 24 h. Control wells
(labeled CM) contain 8 mM Gln (Sigma G7513) and 10% DFBS for the full 24 h. Cells
simultaneously starved of leucine and glutamine were shifted to Leu/Gln-free DMEM
(MP Biomedicals 1642149) for 24 h supplemented with 10% DFBS. Control wells (CM)
contain 8 mM Gln and 0.8 mM Leu (Sigma L8912) for the full 24 h.

Amino acid re-feed experiments
Samples were re-fed with 8 mM L-Gln or 0.8 mM L-Leu for the last hour of the
experiment. Samples re-fed with 4 mM dimethyl-2-oxoglutarate (DMαKG) (Sigma
349631) or 10 mM L-aspartic acid β-methyl ester hydrochloride (βMD) (Sigma A8291)
were added to cells for 2 h.

PLD inhibitor treatments
PLD inhibitor (PLDi) treated samples were simultaneously given 10 µM VU0359595 to
inhibit PLD1, and 10 µM VU0285655-1 to inhibit PLD2 for 1 h. Control lanes were
treated with DMSO.
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siRNA treatment
Transient siRNA transfections were carried out as described previously (Patel et al.,
2016). Cells were plated in 6-well plates in complete medium containing 10% FBS. The
following day, transfections with siRNA (100 nM) in Lipofectamine RNAiMAX
(Thermo Fisher Scientific 137780) were performed in Opti-MEM reduced serum media
(Thermo Fisher Scientific 31985070). After 6 hours, cells were given 10% FBS, and the
following day, the cells were shifted to complete media with 10% FBS. Cells were then
allowed to incubate for indicated times for each experiment, as described in the figure
legends. The following siRNAs were used in the study: Arf1 siRNA (Ambion 4457298),
GDH1 siRNA (Ambion 4427038), RalA siRNA (Ambion 4427037), and non-targeting
siRNA (Ambion 4390843) were obtained from Thermo Fisher Scientific; GOT1/AATC
siRNA (sc-45602), GOT2/AATM siRNA (sc-60052), and Arf6 siRNA (sc-43619) were
obtained from Santa Cruz; Rheb siRNA (M-009692-02) was obtained from Dharmacon.

Western blot analysis
Extraction of proteins from cultured cells and Western blot analysis of extracted proteins
were performed as described previously (Patel et al., 2016). Proteins were extracted from
cultured cells in M-PER (Thermo Fisher Scientific 78501). Equal amounts of total
proteins were separated using SDS-PAGE. Proteins were transferred to nitrocellulose
membranes, which were then blocked using 5% non-fat dry milk in phosphate-buffered
saline containing 0.1% tween-20. Membranes were incubated overnight with primary
antibodies, as described in the figure legends. Either anti-mouse, anti-rabbit, or anti-goat
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HRP-conjugated IgG (Protein Tech Group SA00001-1, SA00001-2, or SA00001-3,
respectively) was used for detection using the ECL reagents (Kindle Biosciences, LLC
R1002 or R1003).

Measurement of PLD activity
PLD activity was determined by quantifying the transphosphatidylation reaction in the
presence of 0.8% 1-BtOH as previously described (Utter et al., 2018) with minor
revisions as described below. Cells plated in 6-well dishes were labeled with [3H]myristic acid (3.0 µCi) for the last 4 h of the experiment. For the last 20 min of the
experiment, 0.8% 1-BtOH was added to the cells to create the transphosphatidylation
reaction, producing 3H-phosphatidylbutanol as a readout of PLD activity. Cells were
collected by scraping in the media and were centrifuged to collect a pellet. The pellet was
subsequently washed with PBS, and lysed in 500 µL of ice-cold acidified methanol
(methanol-6N HCl, 50:2). This was added to the first extraction buffer (155 µL NaCl and
500 µL chloroform) and centrifuged at 4°C at 13,300 RPM for 3 min. The lower organic
layer was added to the second extraction buffer (350 µL water, 115 µL 1M NaCl, and 115
µL methanol) and centrifuged as above. The amount of radioactivity in the lower organic
layer was quantified using a scintillation counter, and equal amounts of radioactivity of
the total lipids from each sample were dried under nitrogen along with 10 µL
phosphatidylbutanol standard solution (10 mg/mL). However, to compare the HEK WT
cells to the Rag A/B KO cells, we dried equal volumes of the total lipids under nitrogen
to be normalized to protein concentration later. All of the dried lipid samples were resuspended in 30 µL of spotting solution (chloroform-methanol, 9:1) and applied to a thin
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layer chromatography plate. Thin layer chromatography plates were run in a chamber
containing 100 mL of the upper mobile-phase solution of ethyl acetate-isooctane-glacial
acetic acid-water, 88:40:16:80, for 2.5 h. Plates were allowed to air dry and then placed
in an iodine chamber to detect the presence of lipids. The lipid band corresponding to
phosphatidylbutanol was scraped and placed in scintillation fluid to be quantified as a
measure of PLD activity. For the HEK cells, the amount of radioactivity scraped was
divided by their respective protein concentrations to account for differences between cell
proliferation between the WT and KO cell lines.

Preparation of PA vesicles
PA (16:0, 18:1) vesicles were prepared as previously described (Menon et al., 2017). PA
in chloroform was dried under nitrogen and resuspended in Dulbecco’s phosphate
buffered saline (Thermo Fisher Scientific 14190) and sonicated for 3 min. Cells were
treated with this 300 µM suspension for 30 minutes twice, for a total treatment time of 1
hour.

Quantification and statistical analysis
All statistical details (ie: sample size, P-value summaries) of experiments can be found in
the figures and their corresponding figure legends. Statistical significance was analyzed
using Graph Pad Prism 7 software. For comparisons between two sets of samples, an
unpaired T-test was performed. For multiple comparisons, an unpaired, one-way
ANOVA analysis was performed. All data is plotted as the mean with the standard
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deviation. P-value asterisks are defined as follows: *P≤0.05; **P≤0.01; ***P≤0.001;
****P≤0.0001. Not significant (ns) means P>0.05.
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